Abstract: An adjustment mechanism for use with a chair. The adjustment mechanism is for use on a chair that has a base assembly with an extending pedestal, a seat, a chassis, and a back. Specifically the adjustment mechanism is for use on a chair that utilizes a J-back bar that couples the chassis to the back. The J-back adjustment mechanism allows the angle of the J-back bar and thus, the back to be changed throughout a range of motion. The J-back adjustment assembly includes a casing and an adjustment portion, wherein rotation of the adjustment portion changes the inclination of the J-back bar and, thus, the back with respect to the seat.

Abstract: A multipurpose adjustment mechanism for a synchrotilt chair mechanism and a chair with the mechanism. The synchrotilt chair mechanism is for use on a chair that has a base assembly with an extending pedestal, a seat, and a back. The synchrotilt mechanism includes a chassis that is coupled to the pedestal and a seat plate that is coupled to the chassis and to the chair seat. The seat plate slides relative to the chassis. The synchrotilt mechanism further includes a multipurpose adjustment mechanism that can adjust both the height of the chair as well as the orientation of the seat with respect to the chassis. The multipurpose adjustment mechanism may also lock the seat plate with respect to the chassis, such that the seat will not move when the user reclines the chair.

Abstract: The present invention relates to acyloxymethylcarbamate oxazolidinones. The compounds of the present invention have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria.

Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

Abstract: A multipurpose adjustment mechanism for a synchrotilt chair mechanism and a chair with the mechanism. The synchrotilt chair mechanism is for use on a chair that has a base assembly with an extending pedestal, a seat, and a back. The synchrotilt mechanism includes a chassis that is coupled to the pedestal and a seat plate that is coupled to the chassis and to the chair seat. The seat plate slides relative to the chassis. The synchrotilt mechanism further includes a multipurpose adjustment mechanism that can adjust both the height of the chair as well as the orientation of the seat with respect to the chassis. The multipurpose adjustment mechanism may also lock the seat plate with respect to the chassis, such that the seat will not move when the user reclines the chair.

Abstract: An adjustment mechanism for use with a chair. The adjustment mechanism is for use on a chair that has a base assembly with an extending pedestal, a seat, a chassis, and a back. Specifically the adjustment mechanism is for use on a chair that utilizes a J-back bar that couples the chassis to the back. The J-back adjustment mechanism allows the angle of the J-back bar and thus, the back to be changed throughout a range of motion. The J-back adjustment assembly includes a casing and an adjustment portion, wherein rotation of the adjustment portion changes the inclination of the J-back bar and, thus, the back with respect to the seat.

Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

Abstract: The present invention relates to novel dihydropyrones of Formula I wherein X is NH or NR8, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.

Abstract: The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Abstract: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

Abstract: The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Abstract: The present invention related to novel dihydropyrones possessing 3-position nitrogen atom, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.

Abstract: The blood sampling assembly includes a retractable double-ended needle so that a vial may be passed through an opposed end of the needle to obtain a blood sample. The assembly includes a hollow cylinder including circumferentially spaced seat tabs which allow a needle seat and the needle supported thereon to be released upon rotation of tube with respect to hollow cylinder. The extractor assembly includes a stopper for maintaining a vacuum within tube to withdraw the needle to a retracted position within the tube upon rotation of the tube, the end cap, and the stopper retainer. A stopper tab positioner rotationally connects the stopper to the cylinder.

Abstract: The blood sampling assembly includes a retractable double-ended needle 26 so that a vial may be passed through an opposed end 30 of the needle to obtain a blood sample. The assembly includes a hollow cylinder 10 including circumferentially spaced seat tabs 20 which allow a needle seat 40 and the needle 26 supported thereon to be released upon rotation of tube 62 with respect to hollow cylinder 10. The extractor assembly includes a stopper 66 for maintaining a vacuum within tube 62 to withdraw the needle to a retracted position within the tube 62 upon rotation of the tube 62, the end cap 92, and the stopper retainer 70. A stopper tab positioner 84 rotationally connects the stopper 66 to the cylinder 10.

Abstract: The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Abstract: The present invention related to novel dihydropyrones possessing 3-position nitrogen atom, which inhabit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections, and diseases, including AIDS.

Abstract: This invention pertains to improved antiviral activity of 6,6-disubstituted-5,6-dihydropyran-2-ones caused by judicious placement of certain polar substituents at the 3 and/or 6 positions.The same substituents which enhance the cellular activity also diminish cytotoxicity further enhancing the desirable properties of these agents as antivirals.

Abstract: This invention pertains to improved antiviral activity of 6,6-disubstituted-5,6-dihydropyran-2-ones caused by judicious placement of certain polar substituents at the 3 and/or 6 positions.The same substituents which enhance the cellular activity also diminish cytotoxicity further enhancing the desirable properties of these agents as antivirals.